X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3976) 3976
Book Review (1137) 1137
Publication (199) 199
Book Chapter (26) 26
Conference Proceeding (8) 8
Dissertation (3) 3
Book / eBook (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2994) 2994
humans (2550) 2550
diabetes mellitus, type 2 - drug therapy (1858) 1858
type 2 diabetes (1508) 1508
male (1425) 1425
endocrinology & metabolism (1368) 1368
diabetes (1246) 1246
dipeptidyl-peptidase iv inhibitors - therapeutic use (1241) 1241
hypoglycemic agents - therapeutic use (1188) 1188
dipeptidyl peptidase-4 inhibitor (1163) 1163
female (1093) 1093
glucagon-like peptide-1 (1034) 1034
animals (912) 912
middle aged (896) 896
sitagliptin (883) 883
dipeptidyl peptidase-4 inhibitors (827) 827
pharmacology & pharmacy (781) 781
glucose (731) 731
aged (726) 726
double-blind (679) 679
metformin (676) 676
glycemic control (660) 660
dipeptidyl-peptidase iv inhibitors - pharmacology (624) 624
treatment outcome (618) 618
diabetes mellitus, type 2 - blood (588) 588
insulin (573) 573
diabetes mellitus (571) 571
hypoglycemic agents (554) 554
hypoglycemic agents - adverse effects (546) 546
dipeptidyl-peptidase iv inhibitors - adverse effects (531) 531
adult (521) 521
type-2 diabetes-mellitus (488) 488
type 2 diabetes mellitus (478) 478
blood glucose - metabolism (473) 473
care and treatment (472) 472
safety (469) 469
adamantane - analogs & derivatives (462) 462
drug therapy, combination (445) 445
vildagliptin (445) 445
drug therapy (434) 434
efficacy (434) 434
analysis (433) 433
blood glucose - drug effects (427) 427
dipeptidyl peptidase 4 - metabolism (418) 418
sitagliptin phosphate (417) 417
hypoglycemic agents - administration & dosage (414) 414
risk factors (414) 414
internal medicine (410) 410
dipeptidyl peptidase-4 (404) 404
hypoglycemic agents - pharmacology (394) 394
research (390) 390
beta-cell function (387) 387
mice (383) 383
dipeptidyl-peptidase iv inhibitors - administration & dosage (369) 369
diabetes therapy (363) 363
medicine, general & internal (361) 361
dpp-4 inhibitor (352) 352
glucagon (345) 345
dextrose (341) 341
mellitus (340) 340
diabetes mellitus, type 2 - complications (337) 337
medicine & public health (336) 336
metformin - therapeutic use (331) 331
glycated hemoglobin a - metabolism (330) 330
linagliptin (329) 329
improves glycemic control (323) 323
peptidase (323) 323
rats (317) 317
hyperglycemia (310) 310
glp-1 (304) 304
insulin resistance (303) 303
peptides (300) 300
abridged index medicus (283) 283
clinical trials (282) 282
diabetes mellitus, type 2 - metabolism (281) 281
adamantane - therapeutic use (279) 279
hypoglycemia (279) 279
double-blind method (278) 278
therapy (273) 273
dosage and administration (267) 267
health aspects (263) 263
cardiac & cardiovascular systems (258) 258
triazoles - therapeutic use (256) 256
dpp-4 inhibitors (254) 254
medicine, research & experimental (254) 254
pyrazines - therapeutic use (253) 253
incretin (242) 242
saxagliptin (231) 231
obesity (230) 230
studies (227) 227
review (222) 222
risk (221) 221
pharmacokinetics (220) 220
oxidative stress (215) 215
inflammation (213) 213
glycosylated hemoglobin (207) 207
drug-naive patients (206) 206
diabetes mellitus, type 2 - physiopathology (205) 205
incretins - therapeutic use (203) 203
monotherapy (200) 200
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3859) 3859
French (27) 27
German (25) 25
Korean (19) 19
Japanese (18) 18
Spanish (13) 13
Russian (12) 12
Hungarian (8) 8
Chinese (4) 4
Italian (3) 3
Polish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 09/2013, Volume 72, pp. 291 - 300
Type 2 diabetes (T2D) is one of the major risk factors associated with Alzheimer's disease (AD). Recent studies have found similarities in molecular mechanisms... 
Type 2 diabetes | Wistar rats | Glucagon-like peptide-1 | Amyloid beta | Tau | Inflammatory markers | Hippocampus | OXIDATIVE STRESS | COGNITIVE IMPAIRMENT | CHOLINESTERASE-INHIBITORS | NEUROSCIENCES | INDUCED EXPERIMENTAL DEMENTIA | INTRACEREBROVENTRICULAR INJECTION | AMYLOID-BETA | HYPERPHOSPHORYLATED TAU-PROTEIN | PAIRED HELICAL FILAMENTS | A-BETA | PHARMACOLOGY & PHARMACY | Tumor Necrosis Factor-alpha - metabolism | Antibiotics, Antineoplastic - toxicity | Rats, Wistar | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | tau Proteins - metabolism | Male | Hippocampus - drug effects | Alzheimer Disease - pathology | Dose-Response Relationship, Drug | Interleukin-1beta - metabolism | Amyloid beta-Peptides - metabolism | Exploratory Behavior - drug effects | Adamantane - therapeutic use | Alzheimer Disease - chemically induced | Adamantane - analogs & derivatives | Disease Models, Animal | Dipeptides - therapeutic use | Glucagon-Like Peptide 1 - metabolism | Alzheimer Disease - drug therapy | Rats | Hippocampus - pathology | Maze Learning - drug effects | Gene Expression Regulation - drug effects | Hippocampus - metabolism | Animals | Dogs | Streptozocin - toxicity | Peptides | Streptozocin | Analysis | Amyloid beta-protein | Drugstores | Development and progression | Alzheimer's disease | Pharmaceutical biotechnology | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2012, Volume 59, Issue 3, pp. 265 - 276
The aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS). The new class of... 
atherosclerosis | dipeptidyl peptidase-4 inhibitors | endothelium | glucagon-like peptide 1 receptor | receptors | inflammation
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk... 
cardiovascular disease | type 2 diabetes | DPP | hypoglycaemia | dapagliflozin | diabetes complications | 4 inhibitor | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | DPP‐4 inhibitor | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 3, pp. 265 - 276
Journal Article
Journal Article
Metabolism, ISSN 0026-0495, 2013, Volume 62, Issue 3, pp. 347 - 351
Abstract Aims/hypothesis Glucagon-like peptide-1 (GLP-1) exerts beneficial effects on the cardiovascular system. Here, we examined the effect of sitagliptin, a... 
Endocrinology & Metabolism | Glucagon-like peptide-1 | Monocytes | Inflammatory cytokines | Atherogenic lipoproteins | MACROPHAGES | ENDOCRINOLOGY & METABOLISM | MICE | ATHEROSCLEROTIC LESION | Multivariate Analysis | Triazoles - administration & dosage | Prospective Studies | Cholesterol - blood | Humans | Middle Aged | Pyrazines - administration & dosage | Interleukin-10 - blood | Cholesterol - immunology | Glucagon-Like Peptide 1 - blood | Male | Inflammation - blood | Glucagon-Like Peptide 1 - immunology | Inflammation - drug therapy | Interleukin-6 - blood | Diabetes Mellitus, Type 2 - immunology | Leukocytes, Mononuclear - immunology | Tumor Necrosis Factor-alpha - immunology | Blood Glucose - immunology | Female | Sitagliptin Phosphate | Leukocytes, Mononuclear - drug effects | Inflammation - immunology | Serum Amyloid A Protein - immunology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Regression Analysis | Diabetes Mellitus, Type 2 - blood | Interleukin-6 - immunology | Diabetes Mellitus, Type 2 - drug therapy | Interleukin-10 - immunology | C-Reactive Protein - immunology | Diabetics | Care and treatment | C-reactive protein | Glucagon | Anti-inflammatory drugs | Low density lipoproteins | Analysis | Insulin resistance | Hypoglycemic agents | Blood lipids | Diabetes | Cholesterol | Index Medicus
Journal Article
by Chen, SM and Zhao, EF and Li, WF and Wang, JH
MEDICINE, ISSN 0025-7974, 12/2017, Volume 96, Issue 48, pp. e8952 - e8952
Background: Previous studies have reported conflicting results for the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitor drugs and acute... 
POPULATION | TRIALS | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | SAXAGLIPTIN | acute pancreatitis | SITAGLIPTIN | meta-analysis | dipeptidyl peptidase-4 inhibitor | THERAPIES | TYPE-2 DIABETES-MELLITUS | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2012, Volume 167, Issue 2, pp. 451 - 457
Journal Article
Journal Article